CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease

Michael Bacher, Richard Dodel, Bayan Aljabari, Kathy Keyvani, Philippe Marambaud, Rakez Kayed, Charles Glabe, Nicole Goertz, Anne Hoppmann, Norbert Sachser, Jens Klotsche, Susanne Schnell, Lars Lewejohann, Yousef Al-Abed

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide " oligomers " and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent gua-nylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk signif cantly reduced Aβ deposition. CNI-1493 treatment resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a signif cant dosedependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD.

Original languageEnglish (US)
Pages (from-to)1593-1599
Number of pages7
JournalJournal of Experimental Medicine
Volume205
Issue number7
DOIs
StatePublished - Jul 7 2008
Externally publishedYes

Fingerprint

Alzheimer Disease
Animal Models
Amyloid beta-Protein Precursor
Anti-Inflammatory Agents
Serum Amyloid A Protein
Poisons
Amyloid Plaques
Amyloid
Cognition
Atrophy
semapimod
Hippocampus
Cell Line
Peptides
Brain

ASJC Scopus subject areas

  • Immunology

Cite this

CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. / Bacher, Michael; Dodel, Richard; Aljabari, Bayan; Keyvani, Kathy; Marambaud, Philippe; Kayed, Rakez; Glabe, Charles; Goertz, Nicole; Hoppmann, Anne; Sachser, Norbert; Klotsche, Jens; Schnell, Susanne; Lewejohann, Lars; Al-Abed, Yousef.

In: Journal of Experimental Medicine, Vol. 205, No. 7, 07.07.2008, p. 1593-1599.

Research output: Contribution to journalArticle

Bacher, M, Dodel, R, Aljabari, B, Keyvani, K, Marambaud, P, Kayed, R, Glabe, C, Goertz, N, Hoppmann, A, Sachser, N, Klotsche, J, Schnell, S, Lewejohann, L & Al-Abed, Y 2008, 'CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease', Journal of Experimental Medicine, vol. 205, no. 7, pp. 1593-1599. https://doi.org/10.1084/jem.20060467
Bacher, Michael ; Dodel, Richard ; Aljabari, Bayan ; Keyvani, Kathy ; Marambaud, Philippe ; Kayed, Rakez ; Glabe, Charles ; Goertz, Nicole ; Hoppmann, Anne ; Sachser, Norbert ; Klotsche, Jens ; Schnell, Susanne ; Lewejohann, Lars ; Al-Abed, Yousef. / CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. In: Journal of Experimental Medicine. 2008 ; Vol. 205, No. 7. pp. 1593-1599.
@article{9bd5f94e01c44378936968e4af4d0268,
title = "CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide {"} oligomers {"} and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent gua-nylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk signif cantly reduced Aβ deposition. CNI-1493 treatment resulted in 70{\%} reduction of amyloid plaque area in the cortex and 87{\%} reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a signif cant dosedependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD.",
author = "Michael Bacher and Richard Dodel and Bayan Aljabari and Kathy Keyvani and Philippe Marambaud and Rakez Kayed and Charles Glabe and Nicole Goertz and Anne Hoppmann and Norbert Sachser and Jens Klotsche and Susanne Schnell and Lars Lewejohann and Yousef Al-Abed",
year = "2008",
month = "7",
day = "7",
doi = "10.1084/jem.20060467",
language = "English (US)",
volume = "205",
pages = "1593--1599",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "7",

}

TY - JOUR

T1 - CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease

AU - Bacher, Michael

AU - Dodel, Richard

AU - Aljabari, Bayan

AU - Keyvani, Kathy

AU - Marambaud, Philippe

AU - Kayed, Rakez

AU - Glabe, Charles

AU - Goertz, Nicole

AU - Hoppmann, Anne

AU - Sachser, Norbert

AU - Klotsche, Jens

AU - Schnell, Susanne

AU - Lewejohann, Lars

AU - Al-Abed, Yousef

PY - 2008/7/7

Y1 - 2008/7/7

N2 - Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide " oligomers " and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent gua-nylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk signif cantly reduced Aβ deposition. CNI-1493 treatment resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a signif cant dosedependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD.

AB - Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide " oligomers " and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent gua-nylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk signif cantly reduced Aβ deposition. CNI-1493 treatment resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a signif cant dosedependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD.

UR - http://www.scopus.com/inward/record.url?scp=46949085484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949085484&partnerID=8YFLogxK

U2 - 10.1084/jem.20060467

DO - 10.1084/jem.20060467

M3 - Article

C2 - 18573905

AN - SCOPUS:46949085484

VL - 205

SP - 1593

EP - 1599

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 7

ER -